Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation
Two Case Reports

Taro Koba, MD, Takashi Kijima, MD PhD, Takayuki Takimoto, MD, PhD, Haruhiko Hirata, MD, Yujiro Naito, MD, Masanari Hamaguchi, MD, Tomoyuki Otsuka, MD, Muneyoshi Kuroyama, MD, Izumi Nagatomo, MD, PhD, Yoshito Takeda, MD, PhD, Hiroshi Kida, MD, PhD, Atsushi Kumanogoh, MD, PhD

Abstract

Rationale: Most of nonsmall cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) activating mutations eventually acquire resistance to the first EGFR-tyrosine kinase inhibitors (TKIs) therapy after varying periods of treatment. Of note, approximately one-third of those patients develop brain metastases, which deteriorate their quality of life and survival. The effect of systemic chemotherapy on brain metastases after acquisition of EGFR-TKI resistance is limited, and thus far, whole-brain radiation therapy, which may cause the harmful effect on neurocognitive functions, has been the only established therapeutic option for especially symptomatic brain metastases. Osimertinib is a third-generation oral, potent, and irreversible EGFR-TKI. It can bind to EGFRs with high affinity even when the EGFR T790M mutation exists in addition to the sensitizing mutations. Its clinical efficacy for NSCLC patients harboring the T790M mutation has already been shown; however, the evidence of osimertinib on brain metastases has not been documented well, especially in terms of the appropriate timing for treatment and its response evaluation.

Patient concerns, Diagnoses, and Interventions: We experienced 2 NSCLC patients with the EGFR T790M mutation; a 67-year-old woman with symptomatic multiple brain metastases administered osimertinib as seventh-line chemotherapy, and a 76-year-old man with an asymptomatic single brain metastasis administered osimertinib as fifth-line chemotherapy.

Outcomes: These patients showed great response to osimertinib within 2 weeks without radiation therapy.

Lessons: These are the first reports to reveal the rapid response of the brain metastases to osimertinib within 2 weeks. These cases suggest the possibility that preemptive administration of osimertinib may help patients to postpone or avoid radiation exposures. In addition, rapid reassessment of the effect of osimertinib on brain metastases could prevent patients from being too late to receive essential radiotherapy.

Abbreviations: BBB = blood brain barrier, CNS = central nervous system, ECOG = Eastern Cooperative Oncology Group, EGFR = epidermal growth factor receptor, NSCLC = non-small cell lung cancer, PS = performance status, TKI = tyrosine kinase inhibitors, WBRT = whole-brain radiation therapy.

Keywords: brain metastasis, osimertinib, case report, epidermal growth factor receptor, nonsmall cell lung cancer, T790M

1. Introduction

The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as the first-generation gefitinib and erlotinib and also the second-generation afatinib showed remarkable activity in nonsmall cell lung cancer (NSCLC) patients harboring EGFR activating mutations.[1–4] However, most patients eventually acquire resistance to the first EGFR-TKI therapy after varying periods of treatment, and approximately one-third of patients develop brain metastases after acquisition of EGFR-TKI resistance.[5,6] Progressions of brain metastases are generally poor prognostic factors in patients with NSCLC,[7,8] and the effect of systemic chemotherapy on brain metastases after acquisition of EGFR-TKI resistance is limited. Thus, whole-brain radiation therapy (WBRT), which may cause harmful effect on neurocognitive functions,[9,10] has been the only option for especially symptomatic multiple brain metastases.[11]

Osimertinib is the third-generation oral, potent, and irreversible EGFR-TKI. It can bind to EGFRs with high affinity even when the T790M mutation exists in addition to the EGFR-TKI-sensitizing mutations.[12] and clinical efficacy has already been shown.[13] However, the effect of osimertinib on the central nervous system (CNS) metastases has not been documented well in clinical situations, except for a few preclinical studies.[14,15]
Furthermore, the time schedules for response evaluation are still controversial. We describe 2 patients who showed great response in symptomatic as well as asymptomatic brain metastases to osimertinib therapy within 2 weeks. Preemptive administration of osimertinib may help patients to postpone or avoid radiation exposures. In addition, rapid reassessment of the effect of osimertinib on brain metastases could prevent patients from being too late to receive essential radiotherapy.

2. Case reports

Written informed consent was obtained from both patients for the publication of this manuscript and accompanying images.

2.1. Case 1

A 67-year-old woman without a history of smoking, who had Behçet’s disease, underwent right middle lobe resection of the lung because of an early stage of NSCLC 9 years ago. Multiple nodules emerged in both lungs on computed tomography (CT) images 7 years ago, which was recognized as a recurrence. An EGFR mutation analysis identified the EGFR L858R mutation in exon 21. Gefitinib was administered as first-line chemotherapy for 2 years and 11 months. After 3 lines of cytotoxic drug regimens (carboplatin plus pemetrexed, tegafur/gimeracil/oteracil plus bevacizumab, and docetaxel), erlotinib was administered as fifth-line chemotherapy and also as EGFR-TKI rechallenge, which failed in 3 and a half months. After 2 courses of vinorelbine administration as sixth-line chemotherapy, the patient complained of unbearable back pain, and spinal MRI examination detected multiple thoracolumbar bone metastases. Radiotherapy was conducted to control pain and prevent fractures. One month later, the patient complained of nausea and decrease of right grip strength. CT images revealed multiple contrast-enhanced nodules throughout the brain (Fig. 1A), and the symptoms were considered to be caused by brain metastases. After intravenous administration of corticosteroids and osmotic diuretics, the symptoms improved immediately. Bronchoscopy had been conducted as re-biopsy, detecting an additional mutation T790M in exon 20. As seventh-line chemotherapy, osimertinib (80mg/day) was administered from the next day the brain nodules were detected, when the grade of Eastern Cooperative Oncology Group (ECOG) performance status (PS) was 3. On day 5 after administration of osimertinib was started, a chest x-ray revealed shrinkage of a right pulmonary nodule (Fig. 2). Grade 3 stomatitis and grade 2 diarrhea, classified by Common Terminology Criteria for Adverse Events version 4.0, emerged on day 9 and day 10, respectively. Osimertinib administration was discontinued on day 11. CT images on day 13 revealed complete remission of brain metastases, except for 1 lesion in the left frontal lobe (Fig. 1B). Nausea and decrease of right grip strength have not recurred, despite discontinuation of corticosteroids and osmotic diuretics. Her ECOG PS gradually improved to 2. In addition, serum alkaline phosphatase was elevated in parallel with tumor shrinkage, probably reflecting the healing process of bone metastases converting from osteolytic to osteoblastic state which is known as the flare phenomenon.\[16,17\]

2.2. Case 2

A 76-year old man, with a 22.5 pack-year smoking history, underwent right upper lobe resection of the lung because of an early stage of NSCLC 10 years ago. An EGFR mutation analysis identified the EGFR exon 19 deletion. Multiple bone metastases as recurrence emerged 6 and a half years ago. Gefitinib was administered as first-line chemotherapy for 4 and a half years. Aftatinib was administered for 10 months as EGFR-TKI rechallenge after sandwiching 4 courses of carboplatin plus pemetrexed with bevacizumab regimen between the EGFR-TKIs. While fourth-line chemotherapy tegafur/gimeracil/oteracil was being administered, pleural effusion with right-sided dominance was seen. A thoracentesis was conducted and detected the additional mutation T790M in exon 20. Osimertinib was administered as fifth-line chemotherapy, when the ECOG PS grade was 2. On day 10 after administration of osimertinib was started, brain CT images revealed the remission of single brain metastasis in the right parietal lobe, which was asymptomatic (Fig. 3). On day 14, decrease of pleural effusion and shrinkage of pulmonary nodules were recognized apparently on a chest x-ray (Fig. 4A). After a month, chest CT images revealed shrinkage of multiple lung metastases and decrease of left-sided pleural effusion (Fig. 4B). His ECOG PS gradually improved to 1, accompanied with the decrease of pleural effusion.

![Figure 1. Contrast-enhanced axial brain CT images of case 1. Multiple metastases at baseline. Complete remission of brain metastases except for 1 (white arrow) in the left frontal lobe after 13 days osimertinib administration. CT=computed tomography.](image-url)
and WBRT was considered within 2 weeks.

to reveal the rapid response of the brain metastases to osimertinib therapy is insufficient. Although there are some reports of effectiveness by dose escalation of EGFR-TKIs,[19,20] pulsatile dosing of EGFR-TKIs[21,22], and switch gefitinib to erlotinib,[23,24] in the AURA phase II extension cohort (NCT01802632) and AURA2 phase II study (NCT02094261), total 162 of 411 patients (39%) had asymptomatic, stable brain metastases at entry.[25] Objective response rate to osimertinib in patients with brain metastases was 56% (88/158; 95%CI 58, 71), comparable to 64% (154/239; 95%CI 58, 71) in patients without brain metastases.[26] Thus, osimertinib may be effective enough in the treatment of NSCLC patients with brain metastases harboring the EGFR T790M mutation.

Overcoming blood brain barrier (BBB) is the key to have enough drug efficacy for CNS metastases, although parenchymal brain metastases may cause BBB disruptions and increase drug penetration to the brain.[26,27] In a few preclinical models, osimertinib was suggested to have therapeutic potential in CNS metastases.[14,15] Ballard and coworkers[15] reported that osimertinib showed a good Kpμ,brain value of 0.39 greater than other available EGFR-TKIs; Kpμ,brain is well established as a good predictor of BBB permeability, with values greater than 0.3 indicative of good diffusion across the BBB.[28]

Compared to parenchymal brain metastases, leptomeningeal metastases appear to have distinct clinical courses and tumor biologies.[29] Leptomeningeal metastases are especially life-threatening CNS complications, and EGFR-TKIs with high permeability to cerebrospinal fluid are essential. By update of ongoing phase I study for patients with leptomeningeal metastases from NSCLC called BLOOM (NCT02228369), osimertinib is expected to have enough efficacy by overcoming the BBB.[30]

WBRT has been the only option for symptomatic multiple brain metastases after acquisition of EGFR-TKI resistance.[31] However, we should consider the potential harmful effect of radiotherapy, especially WBRT. Assessing impairment in neurocognitive function in patients treated with WBRT is difficult, because many variables including dysfunction caused by metastases themselves should be considered. Nonetheless, some studies supported these concerns with reasonable evidence,[9,10] and delaying radiotherapy in favor of osimertinib may be a valuable option.

Although the dramatic responses to EGFR-TKIs are known to be observed in a few days in some cases, the time schedules for response evaluation are still controversial. Chang and coworkers[31] reported that a very high percentage (21/29; 72.4%) of patients who achieved partial response to EGFR-TKI therapy demonstrated an early radiological response in 2 weeks. In addition, we reported that evaluation using F-fluorodeoxyglucose uptake by positron emission tomography on day 2 after the initiation of gefitinib therapy is useful to predict the future clinical outcome of EGFR-TKI therapy at an early time point,[32] although positron emission tomography is not appropriate to assess brain metastases generally.

Osimertinib is the only approved EGFR-TKI currently indicated for NSCLC patients harboring the EGFR T790M mutation. Patients acquire resistance to the osimertinib therapy after a median of 9.6 months of treatment.[13] The EGFR C797S mutation has been reported as a major mechanism (6/15; 40%) of the resistance to osimertinib.[33] Not surprisingly, brain metastases that had developed during the first EGFR-TKI treatment
might respond once to osimertinib therapy but would become resistant. It is unknown whether we should recommend a fourth-generation EGFR-TKI that can overcome the resistance mediated by C797Sor local radiotherapy.

It is the best of all not to develop a brain metastasis in patients who are free of brain metastasis at diagnosis. There is no clinical evidence that supports osimertinib more efficacious in terms of postponing or preventing the development of brain metastases compared with first- and second-generation EGFR-TKIs. A phase III study FLAURA (NCT02296125) is ongoing comparing osimertinib with first-generation EGFR-TKIs as the first-line setting in patients with NSCLC harboring EGFR-activating mutations. This study could reveal if osimertinib will postpone or prevent disease progression by brain metastases compared with first-generation EGFR-TKIs.

In conclusion, osimertinib may be given priority over radiotherapy in terms of the therapeutic strategy for brain metastases of NSCLC harboring the EGFR T790M mutation, and the evaluation of treatment effect might be performed within 2 weeks. Further studies are needed to answer these clinical questions.

References

[1] Nambo Y, Kijima T, Yokota S, et al. Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases. Clin Lung Cancer 2004;6:123–8.

[2] Porta R, Sanchez-Torres JM, Paz-Ares L, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011;37:624–31.

[3] Park J, Kim T, Lee H, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012;77:556–60.

[4] Hofknecht P, Tufran A, Wehler T, et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol 2015;10:156–63.

[5] Mujoomdar A, Austin JH, Malhotra R, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung carcinoma: primary tumor size, cell type, and lymph node metastases. Radiology 2007;242:882–8.

[6] Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res 2010;16:5873–82.

[7] Langer J, Mehta P. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207–19.

[8] Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 2012;18:938–44.

[9] Li J, Bentzen M, Li J, Rentschler M, Mehta P. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastases. Int J Radiat Oncol Biol Phys 2008;71:64–70.

[10] McDuff G, Taich J, Lawson D, et al. Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. J Neurol Neurosurg Psychiatry 2013;84:1384–91.

[11] National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-Small Cell Lung Cancer Version 7.2015, https://www.nccn.org.

[12] Cross A, Ashton E, Ghiorghiu S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046–61.

[13] Janne A, Yang C, Kim W, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689–99.

[14] Nanjo S, Ebi H, Arai S, et al. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget 2016;7:3847–56.

[15] Ballard P, Yates W, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016;22:5130–40. Epub 2016.

[16] Gillespie J, Alexander L, Edelsten A. Changes in 87mSr concentrations in skeletal metastases in patients responding to cyclical combination chemotherapy for advanced breast cancer. J Nucl Med 1975;16:191–3.

[17] Yausuda K, Kawamura K, Ishikado K, Yosshika M. Alkaline phosphatase flare phenomenon following epidermal growth factor receptor-tyrosine kinase inhibitor treatment of non-small cell lung cancer: report of a case and case review. Respir Med Case Rep 2014;13:51–3.

[18] Ricciuti B, Chian R, Charipar P, et al. Osimertinib (AZD9291) and CNS response in two radiotherapy-naive patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer. Clin Drug Investig 2016;36:683–6.

[19] Jackman M, Holmes J, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006;24:4517–20.

[20] Togashi Y, Masago K, Fukudo M, et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 2011;68:1089–92.

[21] Milton T, Arzoli G, Heelan T, et al. A phase III study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 2006;107:1034–41.

[22] Grommes C, Oxnard R, Kris G, et al. Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011;13:1564–9.

[23] Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4:1415–9.

[24] Togashi Y, Masago K, Masuda S, et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 2012;70:399–405.

[25] Ahn M, Tsai C, Yang J, et al. AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: data from phase II studies. Eur J Cancer 2015;51:625–6.

[26] Filid J, Yano S, Zhang D, et al. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002;3:53–7.

[27] Zimmermann S, Dzdzadoszko R, Peters S. Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. Cancer Treat Rev 2014;40:716–22.

[28] Varadarajan S, Winwarter S, Carlsson L, et al. Exploring in silico prediction of the unbound brain-to-plasma drug concentration ratio: model validation, renewal, and interpretation. J Pharm Sci 2015;104:1197–206.

[29] Hata A, Katakami N, Yoshioka H, et al. Prognostic impact of central nervous system metastases after acquired resistance to EGFR-TKIs poorer prognosis associated with T790M-negative status and leptomeningeal metastases, Anticancer Res 2015;35:1025–31.

[30] Yang J, Kim D, Kim S, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. J Clin Oncol 2016;34:abstr9002.

[31] Chang W, Hou M, Hsieh J, et al. Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study. Biomed J 2015;38:221–4.

[32] Takahashi R, Hirata H, Tachibana I, et al. Early [18F]Fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin Cancer Res 2012;18:220–8.

[33] Thress K, Pawedits C, Felip E, et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M. Nat Med 2015;21:560–2.

[34] Suresh R, Yur R, Karen T, Jean-Charles S. A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naive patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation. J Clin Oncol 2015;33:abstr TPS8102.